Cantor Fitzgerald Weighs in on CRNX FY2026 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Crinetics Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($4.87) per share for the year. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($3.73) per share.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.05). The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.10 million. The business's quarterly revenue was down 43.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.93) earnings per share.

Several other analysts also recently issued reports on CRNX. Stifel Nicolaus began coverage on Crinetics Pharmaceuticals in a report on Tuesday, March 25th. They set a "buy" rating and a $60.00 price objective on the stock. TD Cowen assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating on the stock. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $74.56.

Crinetics Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ CRNX traded up $0.80 during mid-day trading on Tuesday, reaching $33.08. The company had a trading volume of 487,929 shares, compared to its average volume of 848,415. Crinetics Pharmaceuticals has a 1-year low of $24.10 and a 1-year high of $62.53. The stock has a market cap of $3.10 billion, a PE ratio of -8.87 and a beta of 0.28. The company has a 50-day moving average price of $30.68 and a two-hundred day moving average price of $38.48.

Institutional Trading of Crinetics Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its stake in shares of Crinetics Pharmaceuticals by 6.3% during the 1st quarter. Rhumbline Advisers now owns 131,950 shares of the company's stock worth $4,426,000 after purchasing an additional 7,872 shares during the last quarter. Strs Ohio acquired a new position in Crinetics Pharmaceuticals during the first quarter worth $124,000. Intech Investment Management LLC increased its position in Crinetics Pharmaceuticals by 32.1% during the first quarter. Intech Investment Management LLC now owns 56,950 shares of the company's stock worth $1,910,000 after buying an additional 13,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Crinetics Pharmaceuticals by 6.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock valued at $11,658,000 after buying an additional 22,305 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new stake in shares of Crinetics Pharmaceuticals in the first quarter worth about $1,720,000. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Crinetics Pharmaceuticals

In related news, insider Dana Pizzuti sold 2,515 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total transaction of $86,013.00. Following the completion of the sale, the insider now directly owns 72,233 shares in the company, valued at approximately $2,470,368.60. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard Scott Struthers sold 17,338 shares of the company's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $592,959.60. Following the completion of the transaction, the chief executive officer now directly owns 329,147 shares in the company, valued at approximately $11,256,827.40. The trade was a 5.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,015 shares of company stock valued at $923,913 in the last quarter. Company insiders own 4.60% of the company's stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.